Search
Close this search box.
Search
Close this search box.

How Syngene’s safety tox package helped Cytopeutics to advance its cell therapy drug to the Clinic

Learn how Cytopeutics partnered with Syngene to conduct safety and tumorigenicity studies for its hMSC product in appropriate animal models as per regulatory guidelines.

 

Author

Latest Blogs

Harnessing the power of induced proximity-based drugs and precision medicine for treating cancer

More
PROTAC-blog

Five questions that determine the success of your PROTAC programs

More
Solving-problems-with-science

Solving problems with science: Gene to GMP-grade clinical supply in nine months

More
Blog-Sustainability-at-Syngene

Minimizing environmental footprint the Syngene way

More

Driving operational excellence with SQDECC

More

How Organocatalysis discovered by Nobel laureates revolutionised drug development and production in Syngene

More

Explore more

Blog

Read our blogs for industry insights and best practices…

More
More

InstaVisit

Visit Syngene virtually via our 360 degree lab tours…

More
More

Webinar

View our webinars on cutting edge science topics and insights…

More
More

Point of View

Read our latest PoVs and White papers….

More
More

Get in touch

© 2023. Syngene International Limited

Twitter Linkedin-in Youtube Facebook-f

Quick Links

Business

Get In Touch

Other Links

Twitter Linkedin-in Youtube Facebook-f

© 2023. Syngene International Limited

To view or email, Please share your details view

To download, Please share your details

Download PDF

To download, Please share your details